MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease

I.J. Sleeman, R. Lawson, A. Yarnall, G. Duncan, F. Johnston, T. Khoo, D. Collerton, J.P. Taylor, D. Burn (Newcastle upon Tyne, United Kingdom)

Meeting: 2016 International Congress

Abstract Number: 777

Keywords: Basal ganglia, Cognitive dysfunction, Dementia, Parkinsonism

Session Information

Date: Tuesday, June 21, 2016

Session Title: Parkinson's disease: Pathophysiology

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: 1) To determine serum urate and homocysteine concentration at baseline, 18 and 36 months in control and PD participants. 2) To determine if urate or homocysteine levels were predictive of changes in disease severity, Montreal Cognitive Assessment (MoCA) score or mild cognitive impairment (PD-MCI level II) over the first 36 months.

Background: Urate and homocysteine have been postulated as biomarkers for disease progression in Parkinson’s disease (PD). Baseline serum urate concentration has been shown to predict motor but not cognitive decline. The relationship between serum homocysteine concentration and cognitive and motor impairment is not known.

Methods: 154 participants with newly diagnosed PD and 99 age-matched controls participated in data collection as part of the ICICLE-PD study. Participants completed a clinical assessment, Movement Disorders Society Unified Parkinson’s disease Scale Part III (UPDRS III), MOCA and other neuropsychological assessments at baseline, 18 and 36 months. PD-MCI was diagnosed using the MDS criteria. Serum samples were drawn at the same time points and analysed for urate, homocysteine, red cell folate and vitamin B12 concentrations.

Results: Baseline urate was 331.4±83.8 and 302.7±78.0 µmol/L for control and PD participants respectively (p=0.07). Baseline homocysteine was 9.6±3.3 and 11.1±3.8 µmol/L for controls and PD participants respectively (p=0.02). Linear mixed effects modelling showed that declining UPDRS III score was predicted by age, levodopa-equivalent dose (LED) and time (p<0.05 for all). The addition of urate and homocysteine significantly improved the model (χ2=189.5, p<0.01); however only urate over time was a significant predictor of declining motor severity (β=0.2, p=0.014). There were no significant associations between change in cognition and serum urate or homocysteine concentrations.

Conclusions: Low serum urate concentration is associated with worsening motor function; however, neither urate nor homocysteine is correlated with change in cognitive outcomes. Therefore, prolonged low urate levels may be a suitable biomarker for declining motor severity even in early PD.

To cite this abstract in AMA style:

I.J. Sleeman, R. Lawson, A. Yarnall, G. Duncan, F. Johnston, T. Khoo, D. Collerton, J.P. Taylor, D. Burn. Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/urate-and-homocysteine-changes-in-motor-and-cognitive-symptoms-in-newly-diagnosed-parkinsons-disease/. Accessed May 13, 2025.
  • Tweet
  • Email
  • Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/urate-and-homocysteine-changes-in-motor-and-cognitive-symptoms-in-newly-diagnosed-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • #23624 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Three cases of early tremor in the course of Guillain-Barré Syndrome
  • The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • The Role of MRI and DaTscan in Vascular Parkinsonism: A Case Report
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley